|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 奥美拉唑、泮托拉唑、兰索拉唑和埃索美拉唑对反流性食管炎患者症状缓解的比较研究显示文摘目的比较奥美拉唑、泮托拉唑、兰索拉唑和埃索美拉唑对反流性食管炎患者症状缓解之间的差异。方法320例内镜诊断为反流性食管炎患者被随机分为4组,并分别服用奥美拉唑20mg,1次/d,8周;兰索拉唑30mg,1次/d,8周;泮托拉唑40mg,1次/d,8周;埃索美拉唑40mg,1次/d,8周。用six-pointscale(0:无,1:轻度,2:轻度-中度,3:中度,4:中度-重度,5:重度)评价服用4种质子泵抑制剂后7天内的烧心和反流症状。结果埃索美拉唑组的平均烧心积分比其他质子泵抑制剂下降更迅速。埃索美拉唑组第1~5天的烧心症状完全消失率明显高于奥美拉唑组(P值分别为0.0054、0.0072、0.0089、0.0107、0.0134)、兰索拉唑组(P值分别为0.0043、0.0034、0.0044、0.0011、0.0052)、泮托拉唑组(P值分别为0.0156、0.0003、0.0005、0.0024、0.0172)。内镜下反流性食管炎愈合率4组之间无明显差异。结论埃索美拉唑比奥美拉唑、兰索拉唑、泮托拉唑更迅速地减轻反流性食管炎患者的烧心和反流症状。 | 郑日男 | 2009 | 胃肠病学和肝病学杂志2009，18，7： | 39 |
| 2 | 亚太地区胃食管反流病的处理共识:更新版显示文摘背景与目的:自从2004年亚太地区胃食管反流病(GERD)共识发表以来,更多关于GERD流行病学和处理的文献资料相继出现。有必要对这些资料进行循证综述,对共识作出更新。方法:由多学科专家组应用德尔菲(Delphi)法制定共识条文,提呈相关资料,并对证据质量、推荐力度和共识水平进行分级。结果:亚洲GERD发生率日益增加。其危险因素包括老年、男性、种族、家族史、社会经济地位高、体重指数增加和吸烟。对于有典型症状而无报警症状的患者,对质子泵抑制剂(PPI)试验有症状应答具有诊断意义。如PPI试验失败,停止治疗后pH监测结果阴性可排除GERD。窄带成像、胶囊内镜检查和无线pH监测的作用尚未明确。亚洲诊断策略的制定须考虑到并存的胃癌和消化性溃疡。减轻体质量和抬高床头可改善反流症状。PPIs是最有效的内科治疗手段。对于非糜烂性反流病(NERD)患者,按需治疗较为适宜。有慢性咳嗽、喉炎和典型GERD症状的患者在排除非GERD病因后,应予PPI每天两次治疗。如有经验丰富的外科医师,GERD患者可行胃底折叠术。除临床试验外,GERD不应采用内镜治疗。结论:新的诊断方法和内镜治疗的作用有待进一步研究阐明。亚洲GERD诊断策略的制定须考虑到并存的胃癌和消化性溃疡。PPIs仍为治疗的基石。 | Kwong Ming Fock Nicholas J Talley Ronnie Fass Khean Lee Goh Peter Katelaris Richard Hunt Michio Hongo Tiing Leong Ang Gerald Holtmann Sanjay Nandurkar San Ren Lin Benjamin CY Wong Francis KL Chan Abdul Aziz Rani Young-Tae Bak Jose Sollano Khek Yu Ho Sathoporn Manatsathit 钱本余 | 2008 | 胃肠病学2008，13，7： | 21 |
| 3 | 雷贝拉唑结合氟哌噻吨/美利曲辛治疗非糜烂性反流病伴抑郁、焦虑患者的疗效观察显示文摘目的:探讨质子泵抑制剂雷贝拉唑结合氟哌噻吨/美利曲辛(黛力新)治疗非糜烂性反流病(NERD)的临床疗效。方法:选择109例非糜烂性反流病伴抑郁、焦虑患者并随机分为2组,A组57例,给予雷贝拉唑20mg,早、晚餐前各1次,氟哌噻吨/美利曲辛10.5mg,早、中餐后各1次;B组52例,给予雷贝拉唑20mg,早、中餐前各1次,两组疗程均为6周,疗程结束后通过症状记分,判断疗效。结果:治疗6周后,两组患者的烧心、胸痛、反酸等主要症状的积分比较,差异均有统计学意义;A组显效率为86.5%,总有效率为96.1%;B组显效率为67.3%,总有效率为82.3%。两组比较差异有显著性(P<0.05)。结论:对伴有抑郁、焦虑的NERD患者,雷贝拉唑结合氟哌噻吨/美利曲辛治疗是有效的治疗方案之一。 | 马晓鹂 周宇 魏国丽 | 2009 | 中国医院用药评价与分析2009，9，2： | 17 |
| 4 | Characteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy显示文摘AIM:To investigate whether potent acid inhibition is effective in non-erosive reflux disease (NERD) refractory to standard rabeprazole (RPZ) treatment. METHODS:We treated 10 Japanese patients with NERD resistant to standard dosages of RPZ:10 mg or 20 mg od,20 mg bid,or 10 mg qid for 14 d. All patients completed a frequency scale for symptoms of gastroesophageal reflux disease questionnaire frequency scale for the symptoms of GERD (FSSG); and underwent 24 h pH monitoring on day 14. RESULTS:With increased dosages and frequency of administration of RPZ,median intragastric pH significantly increased,and FSSG scores significantly decreased. With RPZ 10 mg qid,potent acid inhibition was attained throughout 24 h. However,five subjects were refractory to RPZ 10 mg qid,although the median intragastric pH in these subjects (6.6,range:6.2-7.1) was similar to that in the remaining five responsive subjects (6.5,range:5.3-7.3). With baseline RPZ 10 mg od,FSSG scores in responsive patients improved by > 30%,whereas there was no significant decrease in the resistant group. CONCLUSION:NERD patients whose FSSG score fails to decrease by > 30% after treatment with RPZ 10 mg od for 14 d are refractory to higher dosage. | Mitsushige Sugimoto Masafumi Nishino Chise Kodaira Mihoko Yamade Takahiro Uotani Mutsuhiro Ikuma Kazuo Umemura Takahisa Furuta | 2011 | World Journal of Gastroenterology2011，17，14： | 10 |
| 5 | 多西他赛腹腔灌注联合卡培他滨治疗晚期胃癌疗效分析显示文摘目的 观察腹腔灌注多西他赛联合卡培他滨(希罗达)治疗晚期胃癌疗效及安全性.方法 共入组经病理证实的晚期胃癌患者40例,治疗方案为多西他赛60 mg,腹腔灌注;希罗达2 000 mg/m2,口服,每天2次,第1~14天用药,之后休息1周,21 d为1个周期,至少用药2个周期后进行疗效评价.结果 化疗4个周期后,完全缓解1例(2.5%),部分缓解24例(60.0%),疾病稳定12例(30.0%),疾病进展3例(7.5%),客观有效率62.5%(25/40),平均中位无进展生存期为6.5个月,平均中位生存期为15.3个月,主要不良反应为骨髓抑制、胃肠道反应及手足综合征.结论 腹腔灌注多西他赛联合希罗达治疗晚期胃癌疗效较好,毒性可耐受. | 任韶韶 李然 梁华 张青山 | 2013 | 现代医药卫生2013，29，17： | 3 |
| 6 | 埃索美拉唑结合黛力新治疗非糜烂性反流病伴抑郁、焦虑患者的临床价值显示文摘目的了解质子泵抑制剂埃索美拉唑结合黛力新治疗非糜烂性反流病(NERD)的临床价值。方法 110例非糜烂性反流病伴抑郁、焦虑患者随机分为2组,A组56例,给予埃索美拉唑20 mg,早、晚餐前各1次,黛力新10.5 mg,早餐后1次;B组54例,给予埃索美拉唑20 mg,早、中餐前各1次,两组疗程均为6周,疗程结束后通过症状记分进行判断疗效。结果治疗6周后,两组患者的烧心、胸痛、反酸等主要症状的积分分别比较,差异均有统计学意义(P<0.05);A组与B组显效率(83.9%,66.6%)和总有效率(96.6%,81.5%)分别比较,差异均有统计学意义(P<0.05)。结论埃索美拉唑结合黛力新治疗NERD伴抑郁、焦虑的患者是有效的治疗方案之一。 | 王壮 周宇 冯晓 | 2014 | 中国现代药物应用2014，8，3： | 2 |
| 7 | 质子泵抑制剂对胃食管反流病夜间反流症状的疗效——华北地区数据分析显示文摘背景:胃食管反流病(GERD)与睡眠障碍密切相关。质子泵抑制剂(PPIs)是改善GERD患者反流症状的主要手段。目的:探讨PPIs在我国华北地区一般GERD人群中对夜间反流症状及其相关睡眠障碍的疗效。方法:本研究为一项多中心前瞻性观察性研究。研究纳入2017年7月—2018年3月就诊于华北地区11家三级医院、有夜间烧心或反酸症状并接受PPIs治疗的成人GERD患者,通过日记卡和问卷调查采集夜间反流症状和反流相关睡眠障碍相关信息,以匹兹堡睡眠质量指数(PSQI)评估睡眠质量。分析PPIs治疗4周后的缓解率以评估药物疗效。结果:共750例GERD患者纳入最终分析,其中78.0%存在夜间反流相关睡眠障碍,56.9%睡眠质量不佳(PSQI评分>5)。PPIs治疗4周后,51.3%的患者夜间反流症状得到缓解,夜间反流症状和反流相关睡眠障碍完全缓解率分别为32.5%和51.5%;PSQI评分从基线期的6.82±3.38下降至4.56±2.50(P<0.05)。结论:PPIs治疗可有效缓解华北地区一般GERD人群的夜间反流症状及其相关睡眠障碍,提高睡眠质量。 | 孙恺蒂 马双 惠洋洋 王彬 朱兰平 陈鑫 王邦茂 | 2021 | 胃肠病学2021，26，6： | 2 |
| 8 | Esomeprazole regimens for reflux symptoms in Chinesepatients with chronic gastrit显示文摘AIM To compare symptom control with esomeprazoleregimens for non-erosive reflux disease and chronicgastritis in patients with a negative endoscopy.METHODS: This randomized, open-label study wasdesigned in line with clinical practice in China. Patientswith typical reflux symptoms for ≥ 3 mo and a negativeendoscopy who had a Gastroesophageal Reflux DiseaseQuestionnaire score ≥ 8 were randomized to initialtreatment with esomeprazole 20 mg once daily eitherfor 8 wk or for 2 wk. Patients with symptom reliefcould enter another 24 wk of maintenance/on-demandtreatment, where further courses of esomeprazole 20mg once daily were given if symptoms recurred. Theprimary endpoint was the symptom control rate at week24 of the maintenance/on-demand treatment period.Secondary endpoints were symptom relief rate, successrate (defined as patients who had symptom reliefafter initial treatment and after 24 wk of maintenancetreatment), time-to-first-relapse and satisfaction rate.RESULTS: Based on the data collected in the modifiedintention-to-treat population (MITT; patients in the ITTpopulation with symptom relief after initial esomeprazoletreatment, n = 262), the symptom control rate showeda small but statistically significant difference in favorof the 8-wk regimen (94.9% vs 87.3%, P = 0.0473).Among the secondary endpoints, based on the datacollected in the ITT population (n = 305), the 8-wkgroup presented marginally better results in symptomrelief after initial esomeprazole treatment (88.3% vs83.4%, P = 0.2513) and success rate over the wholestudy (83.8% vs 72.8%, P = 0.0258). The 8-wkregimen was found to provide a 46% reduction in riskof relapse vs the 2-wk regimen (HR = 0.543; 95%CI:0.388-0.761). In addition, fewer unscheduled visits andhigher patient satisfaction supported the therapeuticbenefits of the 8-wk regimen over the 2-wk regimen.Safety was comparable between the two groups, withboth regimens being well tolerated.CONCLUSION: Chinese patients diagnosed withchronic gastritis achieved marginally better control ofreflux symptoms with an 8-wk vs a 2-wk esomeprazoleregimen, with a similar safety profile. | | 2015 | World Journal of Gastroenterology2015，21，22： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员